Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Kenichi InoueJun NinomiyaTsuyoshi SaitoKei KimizukaMasafumi KurosumiPublished in: BMC cancer (2018)
UMIN000015971 . Registration date: January 1, 2015.